Research Article
Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer

Daixing Hu, 1 Mi Zhou, 2 and Xin Zhu 1

1Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Correspondence should be addressed to Xin Zhu; zhuxinxueyiwuhui@126.com

Received 5 August 2019; Revised 11 October 2019; Accepted 17 October 2019; Published 7 December 2019

1.Background

Renal cell cancer (RCC), the common urological malignancy, was statistically predicted for 73,820 estimated new cases and 14,770 estimated deaths in 2019 in the United States [1]. Although detailed and various histopathological classifications were recommended by World Health Organization [2], clear cell renal cell cancer (ccRCC), papillary renal cell cancer (pRCC), and chromophobe renal cell cancer (chRCC) still remain the major histological types, with ccRCC accounting for the largest proportion. Radical surgical resection is the most effective therapy for RCC; however, approximately 30–40% of cases with ccRCC eventually progress into metastatic status postoperatively [3, 4]. Although systemic adjuvant therapy received limited effects on prognosis of advanced ccRCC, nivolumab, as a programmed death 1 (PD-1) immune checkpoint inhibitor antibody, demonstrated promising improved survival outcome in the metastatic ccRCC [5, 6]. Further investigation into the immune microenvironment of ccRCC is expected to reveal the underlying molecular mechanism and prognostic implications.

The Cancer Genome Atlas (TCGA) provided comprehensive genomic profiles and detailed clinical as well as follow-up information, making it suitable to investigate the correlation between immune and genomic features [7]. To
evaluate the role of infiltrating stromal and immune cells in cancer biology, an algorithm called Estimation of STromal and Immune cells in MAlignant Tumours using Expression data (ESTIMATE) was raised and triggered a few genomic investigations on tumor-associated normal cells [8].

This study aimed to elucidate the correlations between tumor microenvironment and clinical characteristics as well as prognosis in ccRCC and investigate the prognosis-associated genes by a comprehensive exploration of the TCGA database and validation analysis based on the Gene Expression Omnibus (GEO) database.

2. Methods

Gene expression profile and clinical data of 537 ccRCC patients were downloaded from the TCGA database (https://tcga-data.nci.nih.gov/tcga/). Immune and stromal scores were calculated by using the ESTIMATE algorithm. Data analyses of differentially expressed genes (DEGs) were performed using package "limma" with threshold set as log FC (fold change) > 1 and P value < 0.05 [9]. Heatmaps were performed using package "pheatmap." Functional enrichment analyses of DEGs were performed by package “clusterProfiler,” “org.Hs.eg.db," “enrichplot,” and “ggplot2.” Gene ontology (GO) categories consisted of biological processes (BPs) and molecular functions (MFs). KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis was preformed to obtain significant associated pathways of DEGs [10]. The protein-protein interaction (PPI) network of intersected DEGs between stromal score and immune score groups was conducted using the STRING (https://string-db.org) [11]. The Kaplan–Meier method was used to explore DEGs with predictive values in overall survival, and the prognostic DEGs were further validated in a GEO dataset GSE29609. All statistical tests were done with R version 3.5 and GraphPad 7. A P < 0.05 was considered as a statistically significant difference.

3. Results

3.1. Correlation between Immune/Stromal Scores and Clinical Characteristics. A total of 537 ccRCC patients with gene expression profiles and clinical information were collected from the TCGA database. The patients were diagnosed as ccRCC between 1998 and 2013. Among them, 346 cases were male and 191 were female. According to the ESTIMATE algorithm, immune scores were distributed between −693.96 and 3328.21, while stromal scores ranged from −1433.77 to 1411.35.

To evaluate the correlations between clinical characteristics and immune or stromal scores, we compared and plotted the distribution of immune scores and stromal scores stratified by the T status, N status, Fuhrman grade, and AJCC stage. We found that a higher immune score was associated with T3/4 (vs. T1/2, Supplementary Figure 1A, P < 0.001), N1 (vs. N0, Figure 1(b), P = 0.05), M1 (vs. M0, Figure 1(c), P = 0.004), and G3/4 (vs. G1/2, Figure 1(d), P < 0.001). With regard to the AJCC stage, the median average immune scores of stage IV ranked the highest of all stage classifications, while stage I harbored the lowest immune scores, indicating that higher immune scores predicted the advanced AJCC stage with statistical significance (Figure 1(e), P < 0.001). However, high stromal scores were only associated with T3/4 (vs. T1/2, Supplementary Figure 1A, P = 0.03), without evidence to support significant correlation between stromal scores and N status, M status, Fuhrman grade, as well as AJCC stage (Supplementary Figures 1B–E, P > 0.05).

To explore the potential correlations between immune scores and/or stromal scores with overall survival (OS), we retrieved 530 ccRCC cases with detailed follow-up information and divided them into high and low immune or stromal score groups. Kaplan–Meier survival curves (Figure 1(f)) showed that OS of cases with the low-score group of immune scores is longer than the cases in the high immune score group (Figure 1(f), P = 0.04). However, cases with lower stromal scores did not show OS advantage over patients with higher stromal scores (Supplementary Figure 1F, P = 0.22).

3.2. DEGs Associated with Tumor Microenvironment in ccRCC. To investigate the DEGs associated with tumor microenvironment in ccRCC, we compared the gene expression profiles of cases stratified by high vs. low immune scores and/or stromal scores. The heatmaps of DEGs based on immune scores (Figure 2(a)) and stromal scores (Figure 2(b)) in ccRCC were presented for different expressions of genes in the separated specimen. With respect to immune scores, 512 genes were upregulated, while 147 genes were downregulated in the high-score group, compared with the low-score group (log FC > 1, P < 0.05). Moreover, comparison between the high and low stromal score groups showed 259 upregulated genes and 152 downregulated genes (log FC > 1, P < 0.05). Intersect genes between stromal score and immune score groups were achieved by Venn diagrams, with 48 intersective upregulated genes and 47 intersective downregulated genes (Figures 2(c) and 2(d)).

3.3. GO and Pathway Analysis of DEGs. To illustrate the functional implications of DEGs, the intersective DEGs were selected to evaluate biological functions and molecular functions by DAVID 6.8. The top 10 DEG-associated biological functions included humoral immune response, cellular response to tumor necrosis factor, response to tumor necrosis factor, leukocyte proliferation, cell chemotaxis, lymphocyte proliferation, mononuclear cell proliferation, B-cell proliferation, monocyte chemotaxis, and mononuclear cell migration, as demonstrated in Figure 2(e). Moreover, Figure 2(e) also showed the top 10 molecular functions including receptor ligand activity, cytokine activity, cytokine receptor binding, anion transport-membrane transporter activity, serine-type endopeptidase activity, CCR chemokine receptor binding, chemokine activity, chemokine receptor binding, phosphatidylinositol 3-kinase activity, and peroxisome proliferator-activated receptor binding. The potential pathways involved were discovered by using KEGG analysis. These DEGs were enriched in cancer-related pathways including cytokine-cytokine
receptor interaction, NF-kappa B signaling pathway, primary immunodeficiency, and intestinal immune network for IgA production (Figure 2(f)).

3.4. Identification and Validation of Prognosis-Associated DEGs. Kaplan–Meier survival analysis was conducted to identify prognostic DEGs with regard to overall survival of ccRCC patients from the TCGA cohort; finally, 43 DEGs were found to be associated with OS in ccRCC. To validate whether the selected DEGs were also predictive of OS in other population, we searched and downloaded a cohort of 39 ccRCC cases with detailed follow-up information from GEO (Supplementary Table 1). Six DEGs were finally validated to be related to OS, of which three upregulated DEGs including CASP5 (Figure 4(a), \( P < 0.005 \), in the TCGA cohort; Figure 4(b), \( P < 0.002 \), in the GEO validation cohort), HSD11B1 (Figure 4(c), \( P = 0.003 \), in the TCGA cohort), and GROW1 were also validated to be related to OS in the GEO cohort (Figure 4(d), \( P < 0.001 \)).

Figure 1: Immune scores were associated with clinical characteristics and overall survival. (a) Distribution of immune scores stratified by T status and box plot indicates a higher immune score was associated with T3/4 (vs. T1/2, \( P < 0.001 \)). (b) Box plot indicated a higher immune score was associated with N1 (vs. N0, \( P = 0.05 \)). (c) Box plot indicates a higher immune score was associated with M1 (vs. M0, \( P = 0.004 \)). (d) Box plot indicated a higher immune score was associated with G3/4 (vs. G1/2, \( P < 0.001 \)). (e) Box plot indicated a higher immune score was associated with the advanced AJCC stage (\( P < 0.001 \)). (f) Kaplan–Meier survival curves for overall survival of ccRCC stratified by immune scores, indicating that the low-score group harbors survival advantage over the high immune score group (\( P = 0.04 \)).
Figure 2: Exploration of DEGs associated with tumor microenvironment in ccRCC. (a) Heatmap of gene expression profiles of high immune score group and low immune score, log FC > 1, P < 0.05. (b) Heatmap of gene expression profiles of high stromal score group and low stromal score group, log FC > 1, P < 0.05. (c, d) Venn diagrams showed the intersect upregulated (c) or downregulated (d) DEGs between immune and stromal score groups. (e) The top 10 DEG-associated biological functions and molecular functions. (f) The potential pathways obtained by using KEGG analysis.
and VSIG4 (Figure 4(e), $P = 0.03$, in the TCGA cohort; Figure 4(f), $P = 0.05$, in the GEO validation cohort). Three downregulated DEGs included HMGCS2 (Figure 5(a), $P < 0.001$, in the TCGA cohort; Figure 5(b), $P = 0.02$, in the GEO validation cohort), HSD11B2 (Figure 5(c), $P < 0.001$, in the TCGA cohort; Figure 5(d), $P = 0.01$, in the GEO validation cohort), and OGDHL (Figure 5(e), $P < 0.001$, in the TCGA cohort; Figure 5(f), $P = 0.02$, in the GEO validation cohort).

4. Discussion

Tumor microenvironment constructed by tumor-associated normal cells during multistep tumorigenesis exerts a significant role in cancer initiation, progression, and drug resistance [12, 13]. Assessing the fraction of microenvironment-associated cell types may illustrate the role of tumor microenvironment and provide perspectives in cancer research. Among the tumor microenvironment, stromal and immune cells constitute the major noncancer proportion. Based on single-sample gene set-enrichment analysis, immune and stromal scores were calculated to predict tumor purity with the level of infiltrating immune and stromal cells by using ESTIMATE [8]. Tumor purity and infiltrated immune/stromal cells are considered to exert a considerable effect on malignancy progression, clinical conditions, and poor prognosis. A tight association between stromal/immune scores and stage as well as prognosis has been demonstrated in glioma [14, 15].

With regard to RCC, it was regarded as a highly vascularized and immunogenic cancer type, harboring two revolutionary therapeutic landscape including anti-angiogenic therapy and immunotherapy [16]. However, heterogeneous tumor microenvironment partly promoted therapeutic resistance and led to unsatisfied prognosis [17].
Figure 4: Validation of three upregulated DEGs from the TCGA database in the GEO database: Kaplan–Meier survival curve for (a) CASP5 in the TCGA database ($P = 0.005$), (b) CASP5 in the GEO database ($P = 0.002$), (c) HSD11B1 in the TCGA database ($P = 0.003$), (d) HSD11B1 in the GEO database ($P = 0.05$), (e) VSIG4 in the TCGA database ($P = 0.03$), and (f) VSIG4 in the GEO database ($P = 0.05$).
Figure 5: Validation of three downregulated DEGs from the TCGA database in the GEO database: Kaplan–Meier survival curve for (a) HMGCS2 in the TCGA database ($P < 0.001$), (b) HMGCS2 in the GEO database ($P = 0.02$), (c) HSD11B2 in the TCGA database ($P < 0.001$), (d) HSD11B2 in the GEO database ($P = 0.01$), (e) OGDHL in the TCGA database ($P < 0.001$), and (f) OGDHL in the GEO database ($P = 0.02$).
Chevrier et al. performed immune profiling of samples from 73 ccRCC cases and five healthy controls by mass cytometry and identified 17 tumor-associated macrophage phenotypes, 22 T-cell phenotypes, and a distinct immune composition correlated with progression-free survival [18].

This study firstly evaluated the association between the levels of immune cells or stromal cells and clinical characteristics and found that a higher immune score was related to more advanced status of ccRCC, including T status, N status, M status, tumor grade, as well as the AJCC stage. Moreover, this study demonstrated that a higher immune score was associated with a shorter overall survival, which may be explained by the tight connection between the higher immune score and advanced clinical characteristics; however, the underlying mechanism required more exploration.

Moreover, this study compared the DEGs between higher and lower immune score groups as well as stromal score groups and detected 95 intersective DEGs with 48 upregulated and 47 downregulated genes. The GO and KEGG analysis suggested that the intersected DEGs were involved with immune cell proliferation like T cells, lymphocytes, mononuclear cells and immune response, cytokine-cytokine receptor interaction, as well as NF-kappa B signaling pathway. Among the 95 intersective DEGs, only 43 DEGs were proved to be associated with overall survival based on TCGA follow-up data, and six genes were finally validated for prognostic values in another cohort from the GEO database.

Among the six validated DEGs, VSIG4, HSD11B1, and CASP5 were upregulated in both higher immune score and stromal score groups, and high expression of these genes harbored unfavorable OS compared with low expression groups, suggesting that higher expressions of these genes were predictive of less tumor purity and worse prognosis. On the contrary, the other three downregulated genes including HMGCS2, HSD11B2, and OGDHL in higher immune score and stromal score groups indicated higher expressions of these genes were associated with more tumor purity and prognostic advantages.

VSIG4 was found to promote carcinogenesis by inhibiting cytotoxic T-lymphocyte activation and acted as an independent predictive factor for a shorter progression-free survival and overall survival in high-grade glioma patients [19]. Moreover, macrophage-associated VSIG4 was demonstrated to facilitate lung carcinoma and multiple myeloma development, which provided a promising immunotherapeutic target and prognostic indicator [20, 21]. HSD11B1 and HSD11B2 were two isozymes of 11 beta-hydroxysteroid dehydrogenase and modulate glucocorticoid levels and might influence circulating levels of active and inactive glucocorticoids [22]. HSD11B1 exhibits oncogenic potential in primary imatinib-naïve gastrointestinal stromal tumors driven by HSD11B1 copy-number gain or missense mutations [23]. CASP5, as a member of caspase family, promoted angiogenesis of human microvascular endothelial cells by activating the VEGF-1 signal pathway [24]. CASP5 was also found to be associated with bladder cancer development, especially in the selected cases with smoking exposure [25]. HMGCS2 may function as either an oncogene or a tumor suppressor in various human cancers. HMGCS2 protein expression was significantly reduced in prostate cancer tissues, and low HMGCS2 expression was associated with a high Gleason score, pathological grade, and presence of distant metastasis in prostate cancer [26]. However, in rectal cancer, high expression of HMGCS2 predicted poor disease-free survival, local recurrence-free survival, and metastasis-free survival [27]. OGDHL was found to suppress cervical tumorigenesis via inactivation of the AKT signaling pathway in cervical cancer [28]. A significant high methylation level leading to inactivation of OGDHL was observed in colorectal cancer compared with nontumoral marginal samples and might be considered as a biomarker for colorectal carcinogenesis [29].

With further exploration of public databases and wide application of bioinformatic methods, increasing evidence indicated promising biomarkers and predictive signatures in renal cancer. Based on TCGA and International Cancer Genome Consortium (ICGC) cohorts, DYSF, VNN3, TMED3, and TEK were found and validated to exert as promising biomarkers to predict the prognosis of ccRCC patients [30–33]. A 3-mRNA signature consisting of ERG, RRM2, and EGF was constructed to predict survival in papillary renal cell cancer with satisfactory accuracy [34]. A risk score based on 6 lncRNAs was raised and exhibited superior predictive value for prognosis of ccRCC [35].

There are still some advantages and limitations in this study. The TCGA has enough sample size and comprehensive types of genomic data, providing a relatively reliable basis for bioinformatics analysis. Although the results were further validated in other databases, several DEGs with significant clinical significance in ccRCC are still required to be investigated to determine the underlying molecular mechanism.

5. Conclusion

In summary, our study elucidated the close association between immune score and clinical characteristics as well as prognosis in ccRCC. Moreover, six DEGs including CASP5, HSD11B1, VSIG4, HMGCS2, HSD11B2, and OGDHL were explored and validated to exert a predictive value in overall survival of ccRCC.

Abbreviations

ccRCC: Clear cell renal cell cancer
DEG: Differentially expressed gene
GO: Gene ontology
BP: Biological processes
MF: Molecular function
KEGG: Kyoto encyclopedia of genes and genomes
PPI: Protein-protein interaction
STRING: Search tool for the retrieval of interacting genes
TCGA: The cancer genome Atlas
GEO: Gene expression omnibus

Data Availability

Data supporting the findings of this study are available within the article.
Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
DH and XZ designed this study. DH and XZ collected the data. MZ and XZ performed statistical analysis. DH and XZ wrote the paper. All authors read and approved the final version of the paper.

Supplementary Materials
Supplementary Figure 1: associations between stromal scores and clinical characteristics or overall survival. (A) Box plot indicated no significant associations between stromal score and high stromal score group (P = 0.36). (B) Box plot indicated no significant associations between stromal score and overall survival of ccRCC stratified by stromal scores, indicating no significant associations between the low stromal group and high stromal score group (P = 0.22). Supplementary Table 1: baseline characteristics of TCGA and GEO validation cohorts. (Supplementary Materials)

References
[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
[2] H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, “The 2016 WHO classification of Tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours,” European Urology, vol. 70, no. 1, pp. 93–105, 2016.
[3] P. Ghatalia, J. Gordetsky, F. Kuo et al., “Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma,” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, p. 139, 2019.
[4] P. M. Pierorazio, M. H. Johnson, H. D. Patel et al., “Management of renal masses and localized renal cancer: systematic review and meta-analysis,” Journal of Urology, vol. 196, no. 4, pp. 989–999, 2016.
[5] M. Gross-Goupil, T. G. Kwon, M. Eto et al., “Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial,” Annals of Oncology, vol. 29, no. 12, pp. 2371–2378, 2018.
[6] R. J. Motzer, N. M. Tannir, D. F. McDermott et al., “Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma,” New England Journal of Medicine, vol. 378, no. 14, pp. 1277–1290, 2018.
[7] H. Lee, J. Palm, S. M. Grimes, and H. P. Ji, “The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations,” Genome Medicine, vol. 7, no. 1, p. 112, 2015.
[8] K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” Nature Communications, vol. 4, no. 1, p. 2612, 2013.
[9] M. E. Ritchie, B. Shipson, D. Wu et al., “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015.
[10] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.
[11] D. Szklarczyk, A. Franceschini, S. Wyder et al., “STRING v10: protein-protein interaction networks, integrated over the tree of life,” Nucleic Acids Research, vol. 43, no. D1, pp. D447–D452, 2015.
[12] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: thenext generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[13] R. Strausmann, T. Morikawa, K. Shee et al., “Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion,” Nature, vol. 487, no. 7408, pp. 500–504, 2012.
[14] C. Zhang, W. Cheng, X. Ren et al., “Tumor purity as an underlying key factor in glioma,” Clinical Cancer Research, vol. 23, no. 20, pp. 6279–6291, 2017.
[15] D. Jia, S. Li, D. Li, H. Xue, D. Yang, and Y. Liu, “Mining TCGA database for genes of prognostic value in glioblastoma microenvironment,” Aging, vol. 10, no. 4, pp. 592–605, 2018.
[16] C. N. Qian, D. Huang, B. Wondergem, and B. T. Teh, “Complexity of tumor vasculature in clear cell renal cell carcinoma,” Cancer, vol. 115, no. S10, pp. 2282–2289, 2009.
[17] I. Heidegger, A. Pircher, and R. Pichler, “Targeting the tumor microenvironment in renal cell cancer biology and therapy,” Frontiers in Oncology, vol. 9, p. 490, 2019.
[18] S. Chevrier, J. H. Levine, V. R. T. Zanotelli et al., “An immune Atlas of clear cell renal cell carcinoma,” Cell, vol. 169, no. 4, pp. 736–749, 2017.
[19] T. Xu, Y. Jiang, Y. Yan et al., “VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients,” American Journal of Translational Research, vol. 7, no. 6, pp. 1172–1180, 2015.
[20] J. Roh, Y. Jeon, A. N. Lee et al., “The immune checkpoint molecule V-set lg domain-containing 4 is an independent prognostic factor for multiple myeloma,” Oncotarget, vol. 8, no. 35, pp. 58122–58132, 2017.
[21] Y. Liao, S. Guo, Y. Chen et al., “VSIG4 expression on macrophages facilitates lung cancer development,” Laboratory Investigation, vol. 94, no. 7, pp. 706–715, 2014.
[22] T. Mune, H. Morita, T. Suzuki et al., “Role of local 11β-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 2, pp. 864–870, 2003.
[23] C. F. Li, T. T. Liu, J. C. Wang et al., “Hydroxyysteroid 11-beta dehydrogenase 1 overexpression with copy-number gain and missense mutations in primary gastrointestinal stromal tumors,” Journal of Clinical Medicine, vol. 7, no. 11, 2018.
[24] H. Li, Y. Li, L. Cai, B. Bai, and Y. Wang, “Effects of CASP5 gene overexpression on angiogenesis of HMEC-1 cells,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 12, pp. 15794–15800, 2015.
[25] R. D. Mittal, P. Srivastava, T. Mittal et al., “Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians,” European
[26] S. Wan, M. Xi, H.-B. Zhao et al., “HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer,” *Pathology-Research and Practice*, vol. 215, no. 8, Article ID 152464, 2019.

[27] Y.-E. Lee, H.-L. He, Y.-L. Shiue et al., “The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy,” *Tumor Biology*, vol. 36, no. 10, pp. 7675–7683, 2015.

[28] T. Sen, N. Sen, M. G. Noordhuis et al., “OGDH is a modifier of AKT-dependent signaling and NF-κB function,” *PLoS One*, vol. 7, no. 11, Article ID e48770, 2012.

[29] M. Khalaj-Kondori, M. Hosseinnejad, A. Hosseinzadeh, S. Behroz Sharif, and S. Hashemzadeh, “Aberrant hypermethylation of OGDHL gene promoter in sporadic colorectal cancer,” *Current Problems in Cancer*, 2019, In press.

[30] M. Ha, H. Jeong, J. S. Roh et al., “DYSF expression in clear cell renal cell carcinoma: a retrospective study of 2 independent cohorts,” *Urologic Oncology: Seminars and Original Investigations*, vol. 37, no. 10, pp. 735–741, 2019.

[31] M. Ha, H. Jeong, J. S. Roh et al., “VNN3 is a potential novel biomarker for predicting prognosis in clear cell renal cell carcinoma,” *Animal Cells and Systems*, vol. 23, no. 2, pp. 112–117, 2019.

[32] M. Ha, H. Moon, D. Choi et al., “Prognostic role of TMED3 in clear cell renal cell carcinoma: a retrospective multi-cohort analysis,” *Frontiers in Genetics*, vol. 10, p. 355, 2019.

[33] M. Ha, Y. R. Son, J. Kim et al., “TEK is a novel prognostic marker for clear cell renal cell carcinoma,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 4, pp. 1451–1458, 2019.

[34] X. Zhu, J. Tan, Z. Liang, and M. Zhou, “Comprehensive analysis of competing endogenous RNA network and 3-mRNA signature predicting survival in papillary renal cell cancer,” *Medicine*, vol. 98, no. 30, Article ID e16672, 2019.

[35] J. H. Zeng, W. Lu, L. Liang et al., “Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data,” *Journal of Translational Medicine*, vol. 17, no. 1, p. 281, 2019.